What the Supreme Court’s Expected Ruling on Affirmative Action Might Mean for US Health Care
Affirmative action in higher education may soon be abolished by the Supreme Court. The consequences for the physician workforce may be dire.
Greg Curfman
-
Read more: What the Supreme Court’s Expected Ruling on Affirmative Action Might Mean for US Health Care -
Read more: The Most Dangerous Branch: A Review of the Supreme Court’s 2021-2022 Term The Most Dangerous Branch: A Review of the Supreme Court’s 2021-2022 Term
A review of key decisions from the Supreme Court’s 2021-2022 term, including rulings on abortion, concealed carry, and regulatory authority.
-
Read more: Fatty Acids, Skinny Labels: Fish Oil Patent Battle Back in Court Fatty Acids, Skinny Labels: Fish Oil Patent Battle Back in Court
An ongoing patent battle over omega-3 fatty acids may have broad implications for the marketing of generic drugs.
-
Read more: The Patent Trial and Appeal Board Again Survives Supreme Court Review The Patent Trial and Appeal Board Again Survives Supreme Court Review
For the generic drug and biosimilar industries, the Supreme Court’s recent decision in United States v. Arthrex, Inc. comes as a relief.
-
Read more: The Patent Trial and Appeal Board Returns to the Supreme Court The Patent Trial and Appeal Board Returns to the Supreme Court
How the Court decides United States v. Arthrex will have important implications for patent law and for administrative law more generally.
-
Read more: 3 Challenges to Patents on Therapeutic Monoclonal Antibodies 3 Challenges to Patents on Therapeutic Monoclonal Antibodies
Three developments may have effects on the use of patents to fend off competition for therapeutic monoclonal antibodies.
-
Read more: Could Vioxx Make a Comeback? Recalled Drug Receives Orphan Designation Could Vioxx Make a Comeback? Recalled Drug Receives Orphan Designation
Over a decade after being recalled, rofecoxib received orphan drug designation for the treatment of pain caused by hemophilic arthropathy.
-
Read more: All-Payer Claims Databases After Gobeille All-Payer Claims Databases After Gobeille
By Gregory Curfman This new post by Gregory Curfman appears on the Health Affairs Blog in a series stemming from the Fifth Annual Health Law Year in P/Review event held at Harvard Law School on Monday, January 23, 2017. With health care spending approaching 20 percent of Gross Domestic Product (GDP), controlling health care costs is a top priority not only for the federal…
-
Read more: LIVE ONLINE TODAY @ NOON: President-Elect Trump’s Health Policy Agenda: Priorities, Strategies, and Predictions LIVE ONLINE TODAY @ NOON: President-Elect Trump’s Health Policy Agenda: Priorities, Strategies, and Predictions
Webinar: President-Elect Trump’s Health Policy Agenda: Priorities, Strategies, and Predictions Monday, December 19, 2016, 12:00 – 1:00pm WATCH LIVE ONLINE!: https://petrieflom.law.harvard.edu/events/details/president-elect-trumps-health-policy-agenda Submit your questions to the panelists via Twitter @PetrieFlom. Please join the Petrie-Flom Center for a live webinar to address what health care reform may look like under the new administration. Expert panelists will…
-
Read more: Medical Device Tax: Back in the News Post-King Medical Device Tax: Back in the News Post-King
By Gregory Curfman Just when the Affordable Care Act (ACA) has won a second major Supreme Court victory in King v. Burwell, conservative critics of the ACA are back on the attack, this time directing their ire towards the medical device tax. Having lost the battle on subsidies, they are now focusing on the device…